Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.50 |
| ▸ | JAK3 | P52333 | 2/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | TYK2 | P29597 | 1/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | IDH1 | O75874 | 4/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1368113 | 1.00 | JAK2 (0.50) | JAK2JAK3JAK1TYK2NTRK1 | |
| SCHEMBL25397603 | 0.94 | JAK2 (0.49) | JAK2JAK3JAK1TYK2NTRK1 | |
| SCHEMBL1367339 | 0.94 | JAK2 (0.49) | JAK2JAK3JAK1TYK2NTRK1 | |
| Hydrochloric Acid SCHEMBL1366987 | 0.93 | JAK2 (0.49) | JAK2JAK3JAK1TYK2NTRK1 | |
| SCHEMBL1365930 | 0.92 | JAK2 (0.49) | JAK2JAK3JAK1TYK2NTRK1 | |
| SCHEMBL1365928 | 0.92 | JAK2 (0.49) | JAK2JAK3JAK1TYK2NTRK1 | |
| SCHEMBL12140791 | 0.89 | JAK2 (0.54) | JAK2JAK3JAK1TYK2NTRK1 | |
| SCHEMBL1365514 | 0.87 | JAK2 (0.55) | JAK2JAK3JAK1TYK2NTRK1 | |
| SCHEMBL1367863 | 0.87 | JAK2 (0.50) | JAK2JAK3JAK1TYK2NTRK1 | |
| SCHEMBL1367865 | 0.87 | JAK2 (0.50) | JAK2JAK3JAK1TYK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023175932-A1 | THERAPEUTIC AGENT FOR HIGH-RISK MYELOFIBROSIS | 日本新薬株式会社 | 2023-09-21 | — | — | WO | claimed |
| WO-2023176972-A1 | THERAPEUTIC AGENT FOR HIGH-RISK MYELOFIBROSIS | 日本新薬株式会社 | 2023-09-21 | — | — | WO | claimed |
| WO-2022239068-A1 | CYTOKINE STORM INHIBITOR | 日本新薬株式会社 | 2022-11-17 | — | — | WO | claimed |
| US-8673891-B2 | Aminopyrazine derivative and medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2014-03-18 | — | — | US | claimed |
| EP-2394999-B1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2014-01-29 | — | — | EP | claimed |
| EP-2394999-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2011-12-14 | — | — | EP | claimed |
| US-20110288065-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO., LTD. (JP) | 2011-11-24 | — | — | US | claimed |
| WO-2023175932-A1 | THERAPEUTIC AGENT FOR HIGH-RISK MYELOFIBROSIS | 日本新薬株式会社 | 2023-09-21 | — | — | WO | disclosed |
| WO-2023176972-A1 | THERAPEUTIC AGENT FOR HIGH-RISK MYELOFIBROSIS | 日本新薬株式会社 | 2023-09-21 | — | — | WO | disclosed |
| WO-2022239068-A1 | CYTOKINE STORM INHIBITOR | 日本新薬株式会社 | 2022-11-17 | — | — | WO | disclosed |
| US-8673891-B2 | Aminopyrazine derivative and medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| US-8673891-B2 | Aminopyrazine derivative and medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| EP-2394999-B1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2014-01-29 | — | — | EP | disclosed |
| US-8586591-B2 | Aminopyrazine derivative and medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2013-11-19 | — | — | US | disclosed |
| US-20130131082-A1 | Aminopyrazine Derivative and Medicine | NIPPON SHINYAKU CO., LTD (JP) | 2013-05-23 | — | — | US | disclosed |
| US-20130131082-A1 | Aminopyrazine Derivative and Medicine | NIPPON SHINYAKU CO., LTD (JP) | 2013-05-23 | — | — | US | disclosed |
| EP-2394999-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-20110288065-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| US-20110288065-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| US-20080045588-A1 | Preparation and utility of substituted amphetamines | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131082-A1 | Aminopyrazine Derivative and Medicine | MC2R, AGTR2, AGTR1 | JAK2 126/4885JAK3 610/4885JAK1 677/4885 |
| US-20110288065-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | MC2R, CNR1, NPY2R | JAK2 186/4885JAK3 429/4885JAK1 665/4885 |
| US-20080045588-A1 | Preparation and utility of substituted amphetamines | PNMT, TAAR5, COMT | JAK2 3459/4885JAK3 2936/4885JAK1 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.